PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Tuning cancer fate: the unremitting role of host immunity.

Abstract Host immunity plays a central and complex role in dictating tumour progression. Solid tumours are commonly infiltrated by a large number of immune cells that dynamically interact with the surrounding microenvironment. At first, innate and adaptive immune cells successfully cooperate to eradicate microcolonies of transformed cells. Concomitantly, surviving tumour clones start to proliferate and harness immune responses by specifically hijacking anti-tumour effector mechanisms and fostering the accumulation of immunosuppressive immune cell subsets at the tumour site. This pliable interplay between immune and malignant cells is a relentless process that has been concisely organized in three different phases: elimination, equilibrium and escape. In this review, we aim to depict the distinct immune cell subsets and immune-mediated responses characterizing the tumour landscape throughout the three interconnected phases. Importantly, the identification of key immune players and molecules involved in the dynamic crosstalk between tumour and immune system has been crucial for the introduction of reliable prognostic factors and effective therapeutic protocols against cancers.
PMID
Related Publications

Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity.

Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment.

Immuno-oncology: understanding the function and dysfunction of the immune system in cancer.

Cancer immunoediting from immune surveillance to immune escape.

New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape.

Authors

Mayor MeshTerms
Keywords

cancer

immune cells

immunotherapy

Journal Title open biology
Publication Year Start




PMID- 28404796
OWN - NLM
STAT- In-Process
DA  - 20170413
LR  - 20170413
IS  - 2046-2441 (Electronic)
IS  - 2046-2441 (Linking)
VI  - 7
IP  - 4
DP  - 2017 Apr
TI  - Tuning cancer fate: the unremitting role of host immunity.
LID - 170006 [pii]
LID - 10.1098/rsob.170006 [doi]
AB  - Host immunity plays a central and complex role in dictating tumour progression.
      Solid tumours are commonly infiltrated by a large number of immune cells that
      dynamically interact with the surrounding microenvironment. At first, innate and 
      adaptive immune cells successfully cooperate to eradicate microcolonies of
      transformed cells. Concomitantly, surviving tumour clones start to proliferate
      and harness immune responses by specifically hijacking anti-tumour effector
      mechanisms and fostering the accumulation of immunosuppressive immune cell
      subsets at the tumour site. This pliable interplay between immune and malignant
      cells is a relentless process that has been concisely organized in three
      different phases: elimination, equilibrium and escape. In this review, we aim to 
      depict the distinct immune cell subsets and immune-mediated responses
      characterizing the tumour landscape throughout the three interconnected phases.
      Importantly, the identification of key immune players and molecules involved in
      the dynamic crosstalk between tumour and immune system has been crucial for the
      introduction of reliable prognostic factors and effective therapeutic protocols
      against cancers.
CI  - (c) 2017 The Authors.
FAU - Cali, B
AU  - Cali B
AUID- ORCID: http://orcid.org/0000-0002-9090-9992
AD  - Department of Biomedical Sciences, University of Padua, Padua, Italy
      [email protected]
AD  - Venetian Institute of Molecular Medicine, Padua, Italy.
FAU - Molon, B
AU  - Molon B
AD  - Department of Biomedical Sciences, University of Padua, Padua, Italy.
AD  - Venetian Institute of Molecular Medicine, Padua, Italy.
FAU - Viola, A
AU  - Viola A
AD  - Department of Biomedical Sciences, University of Padua, Padua, Italy.
AD  - Venetian Institute of Molecular Medicine, Padua, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Open Biol
JT  - Open biology
JID - 101580419
OTO - NOTNLM
OT  - cancer
OT  - immune cells
OT  - immunotherapy
EDAT- 2017/04/14 06:00
MHDA- 2017/04/14 06:00
CRDT- 2017/04/14 06:00
PHST- 2017/01/09 [received]
PHST- 2017/03/14 [accepted]
AID - rsob.170006 [pii]
AID - 10.1098/rsob.170006 [doi]
PST - ppublish
SO  - Open Biol. 2017 Apr;7(4). pii: 170006. doi: 10.1098/rsob.170006.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>